Fig. S1. Infliximab (IFX) suppresses Crohn's disease (CD) peripheral blood (PB) CD4+ T cell interleukin (IL)-21 and IL-17A mRNA expression and T helper type 17 (Th17) cell differentiation. Purified PB CD4+ T cells (1 × 106/ml) from CD patients and healthy controls were stimulated with anti-CD3 (5 μg/ml) and anti-CD28 (2 μg/ml) in the absence or presence of IFX (50 μg/ml) and IL-21R/Fc (20 μg/ml). After 48 h of culture the cultured PB CD4+ T cells were harvested, followed by extraction of total RNA, and levels of IL-21 (A), IL-17 (B) and Th17 cell transcription factor retinoic orphan receptor C (RORC) (C) were then analysed by quantitative real-time polymerase chain reaction (PCR). Gene expression was normalized to β-actin mRNA levels in each sample. Data represent average fold increases or decreases over baseline levels in healthy controls cultured in medium alone (defined arbitrarily as 1·0). *P < 0·005 versus healthy controls under the same stimulatory conditions. +P < 0·05 versus data from the same group cultured in medium alone. ΔP < 0·05 versus data from the same group stimulated with anti-CD3 and anti-CD28 monoclonal antibodies (mAbs). #P < 0·05 versus data from the same group stimulated with anti-CD3 and anti-CD28 mAbs in the presence of IFX.

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.